Search Results

Displaying Results 2501-2525 of 28079 "'FORM'"

Aug 06, 2026, 16:10 ET Republic Services, Inc. Reports Second Quarter 2026 Results

read the following information in conjunction with our audited consolidated financial statements and notes thereto appearing in our Annual Report on Form 10-K as of and for the year ended December 31, 2025. All amounts below are in millions and as a percentage of our revenue, except per share data.REVENUEThe

More news about: Republic Services, Inc.


Aug 06, 2026, 16:09 ET Saul Centers, Inc. Reports Second Quarter 2026 Earnings

assurance that its expectations will be attained.  These factors include, but are not limited to, the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2025 and other periodic or current reports filed with the SEC and include the following: (i) macroeconomic conditions,

More news about: Saul Centers, Inc.


Aug 06, 2026, 16:07 ET THE REALREAL ANNOUNCES SECOND QUARTER 2026 RESULTS

and Analysis of Financial Condition and Results of Operations" in the company's most recent Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q, copies of which may be obtained by visiting the company's Investor Relations website at

More news about: The RealReal


Aug 06, 2026, 16:05 ET Astrana Health, Inc. Reports Second Quarter 2026 Results

SEC, including, without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent quarterly reports on Form 10-Q. Any forward-looking statement made by the Company in this release speaks only as of the date on which

More news about: Astrana Health, Inc.


Aug 06, 2026, 16:05 ET Cryoport Reports Second Quarter 2026 Financial Results

other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the

More news about: Cryoport, Inc.


Aug 06, 2026, 16:05 ET QuidelOrtho Reports Second Quarter 2026 Financial Results

those discussed in QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent reports filed with the Securities and Exchange Commission (the "Commission"), including under Part I, Item 1A, "Risk Factors" of the Form 10-K. You should not rely on forward-looking statements

More news about: QuidelOrtho Corporation


Aug 06, 2026, 16:05 ET Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 7, 2026, and our other

More news about: Amphastar Pharmaceuticals, Inc.


Aug 06, 2026, 16:05 ET PRA Group Reports Second Quarter 2026 Results

Group, Inc.'s filings with the Securities and Exchange Commission, including PRA Group, Inc.'s annual reports on Form 10-K, its quarterly reports on Form 10-Q and its current reports on Form 8-K, which are available through PRA Group, Inc.'s website and contain a detailed discussion of PRA Group, Inc.'s

More news about: PRA Group, Inc.


Aug 06, 2026, 16:05 ET Rocket Companies Announces Second Quarter 2026 Results

settlement services). See "Segments" footnote in the "Notes to Unaudited Condensed Consolidated Financial Statements" in the Company's forthcoming filing on Form 10-Q for more information.Balance Sheet and LiquidityTotal available cash and cash equivalents on

More news about: Rocket Companies, Inc.


Aug 06, 2026, 16:05 ET Gen Further Accelerates in Q1 FY27 and Raises Full Year Guidance

performance. Additional information concerning these and other risk factors is contained in the Risk Factors sections of our most recent reports on Form 10-K and Form 10-Q. We encourage you to read those sections carefully. There may also be other factors that have not been anticipated or are not described

More news about: Gen Digital Inc.


Aug 06, 2026, 16:05 ET Genpact Reports Second Quarter 2026 Results

as other risks detailed in our reports filed with the U.S. Securities and Exchange Commission, including Genpact's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These filings are available at www.sec.gov. Genpact may from time to time make

More news about: Genpact


Aug 06, 2026, 16:05 ET CleanSpark Reports Third Fiscal Quarter 2026 Results

which we record in our Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income as provided in ASC 350-60 and discussed in the Form 10-K. Loss (gain) on fair value of bitcoin, net totaled a loss of $116,250 and a gain of $268,651 in the three months ended June 30, 2026 and 2025,

More news about: CleanSpark, Inc.


Aug 06, 2026, 16:05 ET Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook

products; (xiii) risks associated with our common stock; and (xiv) the other important factors described in our most recently filed Annual Report on Form 10-K and subsequent other filings with the Securities and Exchange Commission.These documents are available in the Investor Relations section

More news about: Shoulder Innovations


Aug 06, 2026, 16:05 ET MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking

More news about: MetaVia Inc.


Aug 06, 2026, 16:05 ET Artivion Reports Second Quarter 2026 Financial Results

anticipated timelines. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-Q for the quarter ended June 30, 2026. Artivion does not undertake to update its forward-looking statements, whether as a result of new information,

More news about: Artivion, Inc.


Aug 06, 2026, 16:05 ET ICF Reports Second Quarter 2026 Results

results to differ materially from those indicated in our forward-looking statements are described in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2025, and in our subsequent filings with the Securities and Exchange Commission. The forward-looking statements

More news about: ICF


Aug 06, 2026, 16:05 ET Csquare Reports Record Second Quarter 2026 Results

Company's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" section of the Company's Registration Statement on Form S-1.Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except

More news about: Csquare, Inc.


Aug 06, 2026, 16:05 ET LIONSGATE REPORTS RESULTS FOR FIRST QUARTER FISCAL 2027

information in this press release should be read in conjunction with the financial statements and footnotes contained in Lionsgate's Quarterly Report on Form 10-Q for the period ended June 30, 2026, which will be posted on Lionsgate's website at

More news about: Lionsgate


Aug 06, 2026, 16:03 ET Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company

Catalyst's SEC reports, including, but not limited to, the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, expected to be filed with the SEC on or about August 6, 2026, and the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026

More news about: Health Catalyst


Aug 06, 2026, 16:03 ET BioMarin Reports Second Quarter 2026 Financial and Operating Results

Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance

More news about: BioMarin Pharmaceutical Inc.


Aug 06, 2026, 16:02 ET 10x Genomics Reports Second Quarter 2026 Financial Results

the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 filed on February 12, 2026 and the company's quarterly report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the U.S. Securities and Exchange Commission ("SEC"), and elsewhere in the documents 10x Genomics,

More news about: 10x Genomics, Inc.


Aug 06, 2026, 16:01 ET STAG INDUSTRIAL RECEIVES 'BBB' INVESTMENT GRADE RATING FROM S&P GLOBAL RATINGS

expectations include, but are not limited to, the risk factors discussed in the Company's annual report on Form 10-K for the year ended December 31, 2025 as updated by the Company's quarterly reports on Form 10-Q. Accordingly, there is no assurance that the Company's expectations will be realized. Except as

More news about: STAG Industrial, Inc.


Aug 06, 2026, 16:01 ET CarParts.com Reports Second Quarter 2026 Results

filings with the Securities and Exchange Commission (the "SEC"), including the Risk Factors contained in the Company's Annual Report on Form 10–K and Quarterly Reports on Form 10–Q, which are available at www.carparts.com/investor and the SEC's

More news about: CarParts.com, Inc.


Aug 06, 2026, 16:01 ET BRC Group Holdings, Inc. Reports Second Quarter 2026 Financial Results

SEC, including, without limitation, the risks described in the Company's 2025 Annual Report on Form 10-K, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Forward-looking statements speak only as of the date

More news about: BRC Group Holdings, Inc.


Aug 06, 2026, 16:01 ET HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, including under the headings "Risk Factors" and "Management's Discussion and

More news about: Halozyme Therapeutics, Inc.


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.